Skip to main content
. Author manuscript; available in PMC: 2018 Jul 28.
Published in final edited form as: Cancer Lett. 2017 Apr 12;399:29–43. doi: 10.1016/j.canlet.2017.04.005

Figure 4. Overexpression of IFITM1 enhances the aggressive phenotype of MCF-7 breast cancer cells in vitro.

Figure 4

(a) IFITM1 expression in MCF-7 cells expressing scrambled control (MCF-7/C9Con) or an IFITM1 guided Cas9 overexpression vector (MCF-7/IF-1 and MCF-7/IF-2) was determined by immunoblotting and compared to expression in MCF-7:5C cells. (b) The proliferation of parental MCF-7, MCF-7/C9Con and MCF-7/IF-2 cells in estrogen containing media was measured over 96 hours by Cell Viability assay. (c) siRNA knockdown of IFITM1 in MCF-7/IF-2 cells over 96 hours demonstrated the specificity of IFITM1 overexpression. (d) Scratch assay was conducted on 70 % confluent plates of MCF-7/C9Con and MCF-7/IF-2 cells. Plates were imaged at 0, 24 and 48 hours and the size of the wound was quantified by image J (right panel). Values represent two independent experiments conducted in triplicate. (e) A direct comparison of proliferation in estrogen and estrogen free media is shown at 96 hours. (f) MCF-7/C9Con and MCF-7/IF-2 were subjected to soft agar anchorage independent growth assay. Plates were imaged after 21 days and the number of colonies was quantified using Image J (lower panel). Values represent two independent experiments conducted in duplicate. *p < 0.05, ** p< 0.01